boston745
5 hours ago
Turns out it is illegal for a conspiracy of funds to buy and naked sort an offering when they work together all while trading inside information. This group of funds did this multiple times between 2022 RS and 2024 RS.
“Short-swing trading is defined as the purchase and sale (or vice versa) of a company’s stock within a six-month period by persons deemed to be ‘insiders,’ who are presumed to have access to confidential corporate information not generally available to other participants in the public mar-ket.” Morales v. Quintel Ent., Inc., 249 F.3d 115, 121 (2d Cir. 2001). An insider is “a person who is directly or indirectly the beneficial owner of more than 10 percent of any class of any equity security.” 15 U.S.C. § 78p(a)(1). The SEC’s regulations do not require that a single person own more than 10%. Instead, a “per-son” will be“deemed a beneficial owner pursuant to section 13(d) of the [Exchange] Act and the rules thereunder.” 17 C.F.R. § 240.16a-1(a)(1); Morales, 249 F.3d at 122. And § 13(d) states that a beneficial owner can be a “group.” 15 U.S.C. § 78m(d)(3) (“When two or more persons act as a . . . group for the purpose of acquiring, holding, or disposing of securities of an issuer, such . . . group shall be deemed a ‘person’ for the purposes of this subsection.”). Consistent with § 13(d), Rule 13d-5(b) states that a group is formed when “two or more persons agree to act together for the purpose of acquiring, holding, voting or disposing of equity securities of an issuer.” 17 C.F.R. § 240.13d-5(b)(1); see alsoRoth v. Jennings, 489 F.3d 499, 507–08 (2d Cir. 2007). That agreement “may be formal or informal and may be proved by direct or circum-stantial evidence.” Morales, 249 F.3d at 124. Finally, to be held liable under § 16(b), a trader must be an insider at the time of both purchase and sale. 15 U.S.C. § 78p(b). And both trades must take place within a six-month window. Id
Augenbaum v. Anson Investments Master Fund LP et al, No. 1:2022cv00249 - Document 142 (S.D.N.Y. 2024)
Court Description: MEMORANDUM OPINION AND ORDER re: 123 MOTION to Dismiss the Amended Complaint. filed by Empery Tax Efficient, LP, L1 Capital Global Opportunities Master Fund, Brio Capital Master Fund Ltd., Empery Debt Opportunity Fund, LP, Emp ery Asset Management, LP, Iroquois Master Fund Ltd., Anson Investments Master Fund LP, Empery Asset Master, LTD., M3A LP, Iroquois Capital Investment Group, LLC, CVI Investments, Inc., Brio Select Opportunities Fund, LP. For these reasons, the defendants' motion to dismiss is DENIED. The Clerk of Court is directed to close Dkt. 123. SO ORDERED. (Signed by Judge Arun Subramanian on 1/24/2024) (jca)
Funds involved in this lawsuit:
Anson Funds Management LP and its affiliates
Ayrton Capital, Altos Opportunity Fund and their
affiliates
Crede Capital Group, Acquitas Capital and its affiliates
CVI Investment, Heights Management, SIG and their
affiliates
Connective Capital and its affiliates
Empery Asset Management and its affiliates
Intracoastal Capital LP and its affiliates
Hudson Bay Capital Management and its affiliates
Ionic Venture LLC and its affiliates
Lind Partners and its affiliates
Li Capital Global Opportunities Master Fund and their
affiliates
Sabby Management LLC and its affiliates
https://law.justia.com/cases/federal/district-courts/new-york/nysdce/1:2022cv00249/573076/142/
========================================
TA, Tesla is going up because it beat Wallstreet expectation which had to be lowered for it to "beat expectations". It was 448k in May and dropped to 436k with Tesla exceeding 436k. Its being pumped for SpaceX offering. Tesla is a fake it until it makes it scam and whats going on is further illustration of it. Of course youd be part of the short and distort here and the pump n dump there.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174085276
SpaceX Reportedly Valued At Around $210 Billion In Planned Secondary Market Share Sale
No wonder TSLA is being pumped right now, theres an offering for SpaceX ongoing. I should have known. As the two companies share shareholders and they sell their Tsla profits to help fund SpaceX offerings. The same thing happened last year around this time.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174694262
boston745
6 hours ago
This is essentially how the Anson family of funds (is Anson at the top of this family?) work SINT and its offerings.
Here is a trade that is almost guaranteed to make money, though it is also double super illegal.
These companies -- there were 13 of them, all pretty small -- raised money through what the SEC calls "confidentially marketed public offerings." A company would engage an investment bank, which would call up potential investors and ask if they wanted to buy shares in the company. The bank would do this before the company publicly announced the offering, and would "wall-cross" the potential investors, making them agree to keep the information about the offering secret until it was announced publicly.
So here's a predictable stock-market pattern and an easy way to exploit it: If a company calls you up to ask you to invest in its upcoming public offering, you should (1) say yes, (2) sell the company's stock short before the public announcement, and then (3) buy the stock back in the public offering, generally at a 10+ percent discount, a few days later.
This is of course not legal advice! It is a great trade, but it is also double super illegal, insofar as:
There is a specific SEC rule against short selling stock just before a public offering and then buying back the stock in the offering, 5 and
There is a general, and much more important, rule against trading on purloined material nonpublic information, and this is that.
trading in breach of that agreement, you are clearly violating not just the contract, but also insider trading laws, which make it illegal to trade "in breach of a fiduciary duty or other relationship of trust and confidence, while in possession of material, nonpublic information about the security."
But, you know, who will check?
Some of the funds would get wall-crossed, and then they'd tip each other and trade in the other funds to try to obscure what was going on:
When they were successful in obtaining such information, Fishoff shorted the issuer’s stock in advance of the offerings, directed trading by Chernin and Costantin in those instances when he did not place the trades on his own, and tipped Petrello, who then also shorted the stock through Brielle and Oceanview.
In many instances, the Fishoff-controlled entities for which Chernin and Costantin were fronting also participated in the offering, with the stock going to Featherwood’s account and often being used to cover the short sales.
This right here is most likely how this family of funds worked. 1+ of them would get information of a forthcoming offering which it would later participate in, and tip the others off so they can pre-short. Not sure why the author says pre-short, wouldnt this be naked shorting? They then used the shares from the offering that Fund #1 received to cover those naked short positions?
By cheating on their wall-cross agreements and shorting the stock, these guys had the effect of driving down the stock price, which probably reduced the price in the offering. These companies probably got less money for their stock because their nonpublic information was (allegedly) used against them.
Though you could have a more cynical view of this sort of thing. A company needs to sell stock, but worries that announcing a public offering will drive down its stock price and not produce any takers. So it calls some investors up privately and tells them it's doing a deal. Those investors agree to invest in the deal, but before the deal is announced they lay off their risk by shorting the company's stock. Then the deal is announced and the investors buy shares from the company to (illegally) cover their shorts. The investors get their 10 percent, or whatever, discount to the market price as a commission; their real function is not to invest in the deal but to intermediate between the company (which can't sell stock without a publicly disclosed offering) and the unsuspecting public (which buys from the "investors" before the public disclosure). The wall-cross agreement creates deniability for the company. No one's stealing from the company; they're helping the company get a deal done that would otherwise be much harder to achieve. The victims are the public who buy from the insider traders at the inflated, pre-announcement price.
There is definitely evidence supporting this, especially between 2022 RS & 2024 RS. For instance, Lind Group participated in the offering, these funds naked shorted from as high as .50s before Lind used their shares to cover those shorts at .15. Thus this group of funds "laid off their risk", making millions in a few days, and did in fact work as an intermediary between the company and the public as they dumped shares. Lind Group sold off its shares in a matter of days. This group of investors gets a hell of alot more than 10% off these offerings. After factoring in the 200:1 split theyve been shorting since 100 with a hell of a pump and dump between .04 to .22 pre-split (8-44 post split).
You short 16 million, knowing once the offering price is announced, the stock will take a hit. Voila, in 24 to 48 hours you just made 1.6 million by buying back at .15 +
Fund A would be the one that bought the offering, in this case Lind Group. Funds B, etc.. (theres like 9 funds identified so far) would be the ones naked shorting like described here by Joev2. For which i replied:
Its the hfunds that made the $1.6m you describe. Also they NAKED shorted on news of the R&D contract with the army, thus they NAKED shorted from .25-.50 range making alot more than the $1.6m you mentioned. If every .1 represents $1.6m profit then if they have an average Naked short position of .35 then that translates to $3.2m in 24 to 48 hours. Essentially funding the offering in 1-2 day period.
They announced the news on Jan 30th when these funds pre-naked shorted the offering and the offering closed on Feb 2nd. This is exactly the scenario depicted in the above and its accomplished by trading inside information and using multiple hedge funds to bypass the sec rule that prevents funds from shorting before an offering they participate in. Then these funds can wash trade the stock price lower trading back and forth between each other, to make even more money shorting the stock. You can see how many naked shares that remained uncovered by the 2nd of Feb.
20240202|829392604|SINT|5,939,951|SINTX TECHNOLOGIES INC COM COM|0.15
Something posted by XenaLives years ago and it seems to correlate with all this, especially post split as theyve been walking the price down.
The 10000 can be wash traded back and forth freely between colluding computers. Tons of money is made so they can now walk the stock down even lower because risk has been reduced.
Instead of thinking of this as simply colluding computers, think of it as Fund A & Fund B colluding to trade back n forth to walk the price down. Anson and the other funds in the family are well known for this sort of behavior and they couldnt have been more obvious about it after the Feb 2023 offering.
Quote Sources:
https://web.archive.org/web/2019033...aders-made-some-easy-money-on-stock-offerings
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173751723
https://investorshub.advfn.com/boards/replies.aspx?msg=173751723
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139777542
boston745
12 hours ago
The following will show there has in fact been a conspiracy of funds, shorting and distorting SINT & Sintx for the past 9 years. My next post will give some insight into how this family of funds might operate. A third post will show that they target vulnerable but promising companies with valuable assets they can secure significant profits from.
Its worth noting that 3 of the family of funds appear to be accumulating a position, just like what was done to Nano in its lawsuit against this conspiracy of funds. Which means they could be getting ready to make their move. Look how it accumulated its position in Nano and then realize three of its family of hedge funds is currently accumulating positions: Anson Funds Management LP, L1 Capital Global Opportunities Master Fund, Ltd. , Lind Global Fund II LP .
https://i.imgur.com/gRnIWov.jpeg
Conspiracy of Funds
First off lets establish the conspiracy of funds working together. Fortunately, in another unrelated lawsuit, the list has been provided:
Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.
List of potential investors the Plaintiff was referencing. All the funds that seem to be connected are in red.
List named the following:
Anson Funds Management LP and its affiliates
Ayrton Capital, Altos Opportunity Fund and their
affiliates
Crede Capital Group, Acquitas Capital and its affiliates
CVI Investment, Heights Management, SIG and their
affiliates
Connective Capital and its affiliates
Empery Asset Management and its affiliates
Intracoastal Capital LP and its affiliates
Hudson Bay Capital Management and its affiliates
Ionic Venture LLC and its affiliates
Lind Partners and its affiliates
Li Capital Global Opportunities Master Fund and their
affiliates
Sabby Management LLC and its affiliates
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf
History of those Funds stake in AMDA/SINT since 2015
List of Funds that have had stakes in AMDA/SINT at one time or another. The first three listed could be accumulating positions in SINT like what was done to NANO. These three funds are connected.
4/01/2024 L1 Capital Global Opportunities Master Fund, Ltd.
https://www.sec.gov/Archives/edgar/data/1269026/000107997324000472/0001079973-24-000472-index.htm
2024-05-14 13F Anson Funds Management LP 959,297 47
https://fintel.io/so/us/sint
2/07/24 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963824000396/0000929638-24-000396-index.htm
2/16/2023 INTRACOASTAL CAPITAL, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000121390023012455/0001213900-23-012455-index.htm
2/14/2023 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963823000614/0000929638-23-000614-index.htm
05/18/2018 CVI Investments, Inc.
https://www.sec.gov/Archives/edgar/data/1269026/000110465918034362/0001104659-18-034362-index.htm
01/19/2017 SABBY MANAGEMENT, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000153561017000068/0001535610-17-000068-index.htm
07/14/2016 ALPHA CAPITAL ANSTALT
https://www.sec.gov/Archives/edgar/data/1269026/000121390016014963/0001213900-16-014963-index.htm
9/14/2015 Frigate Ventures LP = Anson Group
This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Frigate Ventures LP (d/b/a Anson Group), a Texas limited partnership (“Frigate”), Admiralty Advisors LLC, a Texas limited liability company (“Admiralty”), Mr. Bruce R. Winson, the principal of Frigate and Admiralty, M5V Advisors Inc. (d/b/a Anson Group Canada), an Ontario, Canada corporation (“M5V”), Mr. Adam Spears, a director of M5V, and Mr. Moez Kassam, a director of M5V, relating to Common Stock, $.01 par value (the “Common Stock”), of Amedica Corporation, a Delaware corporation (the “Issuer”).
https://www.sec.gov/Archives/edgar/data/1269026/000119312515319457/0001193125-15-319457-index.htm
Hudson Bay Capital Management LP 2,789,867 2.16 870,438 Sep 30, 2015
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118775462
XenaLives connecting CVI to ALPHA CAPITAL ANSTALT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143618825
Lawsuit Sources:
https://www.sec.gov/Archives/edgar/data/1491072/000119312523131774/d264274dex993.htm
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf
This case connects additional funds to Anson that have not had a stake in SINT in the past like Empery Asset Management.
https://casetext.com/case/augenbaum-v-anson-invs-master-fund-8
boston745
1 day ago
SINTX’s IP protection around the antipathogenic properties of silicon nitride materials was expanded further with the issuance of U.S. Patent No. 12,017,912 – Antipathogenic Devices and Methods Thereof. This patent specifically protects usage of silicon nitride as part of an anti-pathogenic composition designed to treat or prevent infections, particularly fungal infections, in plants. The patent was awarded based on demonstrations that dispersions containing silicon nitride particles could rapidly inactivate fungi, such as Plasmopara viticola, that commonly plague grape vines used in wine production. The supporting research, jointly conducted by SINTX and collaborators, showed that silicon nitride dispersions applied to Cabernet Sauvignon and Cannonau vines could halt fungal infections without harming the plants. Silicon nitride presents an effective low-toxicity alternative to many commercial fungicides.
Management increasing shareholder value through patents! Looks like Si3N4 can be used as an antifungal agent for the wine industry.
https://www.linkedin.com/feed/update/activity:7213621330154332160
boston745
3 days ago
This is essentially how the Anson family of funds (is Anson at the top of this family?) work SINT and its offerings.
Here is a trade that is almost guaranteed to make money, though it is also double super illegal.
These companies -- there were 13 of them, all pretty small -- raised money through what the SEC calls "confidentially marketed public offerings." A company would engage an investment bank, which would call up potential investors and ask if they wanted to buy shares in the company. The bank would do this before the company publicly announced the offering, and would "wall-cross" the potential investors, making them agree to keep the information about the offering secret until it was announced publicly.
So here's a predictable stock-market pattern and an easy way to exploit it: If a company calls you up to ask you to invest in its upcoming public offering, you should (1) say yes, (2) sell the company's stock short before the public announcement, and then (3) buy the stock back in the public offering, generally at a 10+ percent discount, a few days later.
This is of course not legal advice! It is a great trade, but it is also double super illegal, insofar as:
There is a specific SEC rule against short selling stock just before a public offering and then buying back the stock in the offering, 5 and
There is a general, and much more important, rule against trading on purloined material nonpublic information, and this is that.
trading in breach of that agreement, you are clearly violating not just the contract, but also insider trading laws, which make it illegal to trade "in breach of a fiduciary duty or other relationship of trust and confidence, while in possession of material, nonpublic information about the security."
But, you know, who will check?
Some of the funds would get wall-crossed, and then they'd tip each other and trade in the other funds to try to obscure what was going on:
When they were successful in obtaining such information, Fishoff shorted the issuer’s stock in advance of the offerings, directed trading by Chernin and Costantin in those instances when he did not place the trades on his own, and tipped Petrello, who then also shorted the stock through Brielle and Oceanview.
In many instances, the Fishoff-controlled entities for which Chernin and Costantin were fronting also participated in the offering, with the stock going to Featherwood’s account and often being used to cover the short sales.
This right here is most likely how this family of funds worked. 1+ of them would get information of a forthcoming offering which it would later participate in, and tip the others off so they can pre-short. Not sure why the author says pre-short, wouldnt this be naked shorting? They then used the shares from the offering that Fund #1 received to cover those naked short positions?
By cheating on their wall-cross agreements and shorting the stock, these guys had the effect of driving down the stock price, which probably reduced the price in the offering. These companies probably got less money for their stock because their nonpublic information was (allegedly) used against them.
Though you could have a more cynical view of this sort of thing. A company needs to sell stock, but worries that announcing a public offering will drive down its stock price and not produce any takers. So it calls some investors up privately and tells them it's doing a deal. Those investors agree to invest in the deal, but before the deal is announced they lay off their risk by shorting the company's stock. Then the deal is announced and the investors buy shares from the company to (illegally) cover their shorts. The investors get their 10 percent, or whatever, discount to the market price as a commission; their real function is not to invest in the deal but to intermediate between the company (which can't sell stock without a publicly disclosed offering) and the unsuspecting public (which buys from the "investors" before the public disclosure). The wall-cross agreement creates deniability for the company. No one's stealing from the company; they're helping the company get a deal done that would otherwise be much harder to achieve. The victims are the public who buy from the insider traders at the inflated, pre-announcement price.
There is definitely evidence supporting this, especially between 2022 RS & 2024 RS. For instance, Lind Group participated in the offering, these funds naked shorted from as high as .50s before Lind used their shares to cover those shorts at .15. Thus this group of funds "laid off their risk", making millions in a few days, and did in fact work as an intermediary between the company and the public as they dumped shares. Lind Group sold off its shares in a matter of days. This group of investors gets a hell of alot more than 10% off these offerings. After factoring in the 200:1 split theyve been shorting since 100 with a hell of a pump and dump between .04 to .22 pre-split (8-44 post split).
You short 16 million, knowing once the offering price is announced, the stock will take a hit. Voila, in 24 to 48 hours you just made 1.6 million by buying back at .15 +
Fund A would be the one that bought the offering, in this case Lind Group. Funds B, etc.. (theres like 9 funds identified so far) would be the ones naked shorting like described here by Joev2. For which i replied:
Its the hfunds that made the $1.6m you describe. Also they NAKED shorted on news of the R&D contract with the army, thus they NAKED shorted from .25-.50 range making alot more than the $1.6m you mentioned. If every .1 represents $1.6m profit then if they have an average Naked short position of .35 then that translates to $3.2m in 24 to 48 hours. Essentially funding the offering in 1-2 day period.
They announced the news on Jan 30th when these funds pre-naked shorted the offering and the offering closed on Feb 2nd. This is exactly the scenario depicted in the above and its occomplished by trading inside information and using multiple hedge funds to bypass the sec rule that prevents funds from shorting before an offering they participate in. Then these funds can wash trade the stock price lower trading back and forth between each other, to make even more money shorting the stock. You can see how many naked shares that remained uncovered by the 2nd of Feb.
20240202|829392604|SINT|5,939,951|SINTX TECHNOLOGIES INC COM COM|0.15
Something posted by XenaLives years ago and it seems to correlate with all this, especially post split as theyve been walking the price down.
The 10000 can be wash traded back and forth freely between colluding computers. Tons of money is made so they can now walk the stock down even lower because risk has been reduced.
Instead of thinking of this as simply colluding computers, think of it as Fund A & Fund B colluding to trade back n forth to walk the price down. Anson and the other funds in the family are well known for this sort of behavior and they couldnt have been more obvious about it after the Feb 2023 offering.
Quote Sources:
https://web.archive.org/web/2019033...aders-made-some-easy-money-on-stock-offerings
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173751723
https://investorshub.advfn.com/boards/replies.aspx?msg=173751723
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139777542
boston745
3 days ago
Notice that on April 1st, L1 filed its 13G indicating it had 8.8% of outstanding stock. Two days later, Sintx announces an offering at 2.1 cents adding 71m shares of stock.
(2) Based on 51,080,139 shares of Common Stock outstanding as reported in the Issuer’s filings with the Securities and Exchange Commission.
Once this offering completed, L1 stake in Sintx became 3.6%.
This indicates that Sonny is not simply raising funds, but that hes preventing these funds from accumulating too large of a position. Thus this game of massive dilution and reverse splits seems to be a game of Sonny defending Sintx from this group of hostile funds. As long as this group of funds continue to attempt to take over Sintx through hostile means, we can expect this to continue. However with Nasdaq putting Sintx on probation for a year, it's limited on its ability to raise funds while diluting this groups position as it must stay over $1. Sintx needs to do a private placement offering which is likely why Sonny has indicated that Sintx is exploring Strategic Opportunities. Sell Sintx Armor to NP Aerospace is one option as NP Aerospace needs a US facility and Utah is a good location for manufacturing and military connections. It could also try to get one of its partners to take a stake. As Ansons group of funds come at you sideways, they'll try to disrupt any such negotiations. Sintx is in a precarious predicament right now. Can Zimmer Biomet not step up already?
SINTX Technologies to Explore Strategic Opportunities
Board of Directors has initiated a process to explore potential strategic options for the Company.
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities
April 1st 13G
https://www.sec.gov/Archives/edgar/data/1269026/000107997324000472/l1cap_13g.htm
April 3rd Press Release
https://ir.sintx.com/news-events/press-releases/detail/225/sintx-technologies-announces-pricing-of-1-3-million-public
boston745
4 days ago
The following will show there has in fact been a conspiracy of funds, shorting and distorting SINT & Sintx for the past 9 years. My next post will give some insight into how this family of funds might operate. A third post will show that they target vulnerable but promising companies with valuable assets they can secure significant profits from.
Its worth noting that 3 of the family of funds appear to be accumulating a position, just like what was done to Nano in its lawsuit against this conspiracy of funds. Which means they could be getting ready to make their move. Look how it accumulated its position in Nano and then realize three of its family of hedge funds is currently accumulating positions: Anson Funds Management LP, L1 Capital Global Opportunities Master Fund, Ltd. , Lind Global Fund II LP .
https://i.imgur.com/gRnIWov.jpeg
Conspiracy of Funds
First off lets establish the conspiracy of funds working together. Fortunately, in another unrelated lawsuit, the list has been provided:
Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.
List of potential investors the Plaintiff was referencing. All the funds that seem to be connected are in red.
List named the following:
Anson Funds Management LP and its affiliates
Ayrton Capital, Altos Opportunity Fund and their
affiliates
Crede Capital Group, Acquitas Capital and its affiliates
CVI Investment, Heights Management, SIG and their
affiliates
Connective Capital and its affiliates
Empery Asset Management and its affiliates
Intracoastal Capital LP and its affiliates
Hudson Bay Capital Management and its affiliates
Ionic Venture LLC and its affiliates
Lind Partners and its affiliates
Li Capital Global Opportunities Master Fund and their
affiliates
Sabby Management LLC and its affiliates
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf
History of those Funds stake in AMDA/SINT since 2015
List of Funds that have had stakes in AMDA/SINT at one time or another. The first three listed could be accumulating positions in SINT like what was done to NANO. These three funds are connected.
4/01/2024 L1 Capital Global Opportunities Master Fund, Ltd.
https://www.sec.gov/Archives/edgar/data/1269026/000107997324000472/0001079973-24-000472-index.htm
2024-05-14 13F Anson Funds Management LP 959,297 47
https://fintel.io/so/us/sint
2/07/24 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963824000396/0000929638-24-000396-index.htm
2/16/2023 INTRACOASTAL CAPITAL, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000121390023012455/0001213900-23-012455-index.htm
2/14/2023 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963823000614/0000929638-23-000614-index.htm
05/18/2018 CVI Investments, Inc.
https://www.sec.gov/Archives/edgar/data/1269026/000110465918034362/0001104659-18-034362-index.htm
01/19/2017 SABBY MANAGEMENT, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000153561017000068/0001535610-17-000068-index.htm
07/14/2016 ALPHA CAPITAL ANSTALT
https://www.sec.gov/Archives/edgar/data/1269026/000121390016014963/0001213900-16-014963-index.htm
9/14/2015 Frigate Ventures LP = Anson Group
This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Frigate Ventures LP (d/b/a Anson Group), a Texas limited partnership (“Frigate”), Admiralty Advisors LLC, a Texas limited liability company (“Admiralty”), Mr. Bruce R. Winson, the principal of Frigate and Admiralty, M5V Advisors Inc. (d/b/a Anson Group Canada), an Ontario, Canada corporation (“M5V”), Mr. Adam Spears, a director of M5V, and Mr. Moez Kassam, a director of M5V, relating to Common Stock, $.01 par value (the “Common Stock”), of Amedica Corporation, a Delaware corporation (the “Issuer”).
https://www.sec.gov/Archives/edgar/data/1269026/000119312515319457/0001193125-15-319457-index.htm
Hudson Bay Capital Management LP 2,789,867 2.16 870,438 Sep 30, 2015
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118775462
XenaLives connecting CVI to ALPHA CAPITAL ANSTALT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143618825
Lawsuit Sources:
https://www.sec.gov/Archives/edgar/data/1491072/000119312523131774/d264274dex993.htm
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf
This case connects additional funds to Anson that have not had a stake in SINT in the past like Empery Asset Management.
https://casetext.com/case/augenbaum-v-anson-invs-master-fund-8
boston745
5 days ago
So Lets examine the value of Sintx and its IP here from a few angles. This should show exactly why Anson's family of funds would be trying to take over Sintx through hostile means. It represents alot of potential money for them if they can succeed. A work in progress.
Transitive Property:
In 2003, Zimmer acquired a materials company for $232m with $108m of it upfront and the remaining $124m coming over the next two years based on sales milestones. Before announcing its partnership with Zimmer, Implex had revenue about the same as Sintx should achieve this year. Its material Hydrocel, Trabeular Metal, could be used for multiple orthopedic implants. Spine, dental, hip, shoulder, and i think knee. That said, Trabecular metal cannot be used as a coating or imbued in materials like silicon nitride can to bring those materials its beneficial enhancements. Thus its market potential just in ortho/dental markets is smaller
Thus Sintx valuation should be at minimum based on what similar companies are worth: $232m
Accumulated Deficit and Tax Write-off
Sintx Accumulated Deficit = $271.6m. For an acquiring company to utilize this for tax write off purposes Sintx IP would have to be valuable enough to bring in sufficient revenue. However as the cost to acquire Sintx would cost millions between accounting audits, lawyers, golden parachutes, etc.. Sintx accumulated Deficit would likely represent about the same value as what Implex was acquired for to an acquiring company. That is only if Sintx IP couldnt generate more revenue than Sintx deficit. The following will show that it can easily.
Also, acquiring Sintx for that amount would increase goodwill which is an asset the acquiring company can depreciate and thus provide additional tax benefit as well as increase its assets.
Potential Market Size
One particular thing about Sintx is its current sales represents a fraction of 1% of its potential revenue because it has not actually transitioned into the commercialization phase yet. The 99% of its products remain in R&D stage. Sort of like a pharma company.
Silicon Nitride increases osteointrgration, improves imaging, and is antimicrobial (antiviral, antibacterial, antifungal) while being bioactive and biodegradable. That means as it corrodes the material breaks down into materials the body can use. For instance in an aqueous solution, Si3N4 turns into orthosilicic acid which the body utilizes for bone growth. Unlike other materials used in orthopeadic implants, Si3N4 shouldnt accumulate in the body as it can be excreted. Meanwhile Titanium, Trabecular Metal, PEEK, ZTA, all accumulate in the tissue, blood and/or organs. Metals seem to spread through the body while other ceramics and plastics mostly accumulate locally. This is all important to understand when you consider that Si3n4 is destined to replace current materials used in the $64 billion ortho implant industry. As Si3n4 can be used as a coating for metal implants and can be imbued in PEEK materials, it could and should capture almost the entire ortho industry but only though partnerships and licensing.
Markets Si3n4 can be used in (not comprehensive)
Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Total = $324.36bn
Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI. However would need to be studied further to ensure it doesnt impact the delicate microbe balance inside a vaginal canal.
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Sources:
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/22/orthopedics-market-set-to-reach-64bn-by-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
========================================
TA, i didnt say what you're claiming i said. Joe said i was ok with management making choices that resulted in me losing all my money. My response was to show how i have not lost it all. My warrants, from the 2022 rights offering, strike price should be 4.20 for instance which is less than the current stock price of 5.38. Thus if i converted and sold, represents a gain.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
boston745
5 days ago
You realize you are disagreeing with something i didnt say because you changed what i said. I said, "You claim to be against these sorts of vulture funds yet your every post is against Sintx/management and therefore in support of those vultures". This means your posts are in support of Anson's family of funds because your posts are only geared against Sintx. I did not say you were in support of Ansons funds even though i think you are based on your posts (even if indirectly). Are you short SINT? Because im long SINT and thus my money is where my mouth is.
If you post against Trump you are in fact indirectly supporting Biden even if you dont want/or will not vote for Biden.
Yes you can flip that around on me but your scenario is wrong. For instance my warrants are in the green for now. I have preferred shares as well that, for the moment, do not convert to many shares. However, if there is future preferred shares issued in a rights offering, i could get a much better conversion price if i am allowed to exchange them for new ones. Sintx has done this before so it could do it again. Thus i have not lost all my money and still stand a chance to make a good amount because of the enormous value here as shown in my last post. My investments are locked up for now, thats a more accurate assessment of my situation. This is what management has done to protect its shareholders against the funds attacking its stock.
Also, i have indicated several times before as long as management and my interests are aligned i support them and so far they are aligned. Sonny has overseen a massive expansion of intellectual property and thus significant increase in shareholder value via Sintx patent portfolio; even if that value is not currrently reflected by the markets. I do not support Sonny taking Sintx private nor do i support him doing any kind of merger with NP Aerospace. If NP Aerospace took a stake in Sintx i could get behind that depending. The reason i do not support Sintx going private is the capital needed to bring products to market is significant. Thus only large public companies can afford that sort of investment. Companies like Zimmer Biomet.
Mantia says investors can also evaluate shareholder value through softer measures such as innovation and competitive dynamics, "which are harder to measure but can be just as important."
For example, a technology company with a strong patent portfolio may be seen as more valuable due to its ability to prevent competitors from copying its technology. Similarly, patents can generate licensing revenue, bolstering a company's financial position. Understanding the strategic value of patents and leveraging them efficiently can positively impact a company's valuation, making it an important aspect to consider in the evaluation of a business.
boston745
5 days ago
So Lets examine the value of Sintx and its IP here from a few angles. This should show exactly why Anson's family of funds would be trying to take over Sintx through hostile means. It represents alot of potential money for them if they can succeed.
Transitive Property:
In 2003, Zimmer acquired a materials company for 232m with 108m of it upfront and the remaining 127m coming over the next two years based on sales milestones. Before announcing its partnership with Zimmer, Implex had revenue about the same as Sintx should achieve this year. Its material Hydrocel, Trabeular Metal, could be used for multiple orthopedic implants. Spine, dental, hip, shoulder, and i think knee.
Thus Sintx valuation should be at minimum based on what similar companies are worth: $232m
Accumulated Deficit and Tax Write-off
Sintx Accumulated Deficit = $271.6m. For an acquiring company to utilize this for tax write off purposes Sintx IP would have to be valuable enough to bring in sufficient revenue. However as the cost to acquire Sintx would cost millions between accounting audits, lawyers, golden parachutes, etc.. Sintx accumulated Deficit would likely represent about the same value as what Implex was acquired for to an acquiring company. That is only if Sintx IP couldnt generate more revenue than Sintx deficit. The following will show that it can easily.
Potential Market Size
One particular thing about Sintx is its current sales represents a fraction of 1% of its potential revenue because it has not actually transitioned into the commercialization phase yet. The 99% of its products remain in R&D stage. Sort of like a pharma company.
Silicon Nitride increases osteointrgration, improves imaging, and is antimicrobial (antiviral, antibacterial, antifungal) while being bioactive and biodegradable. That means as it corrodes the material breaks down into materials the body can use. For instance in an aqueous solution, Si3N4 turns into orthosilicic acid which the body utilizes for bone growth. Unlike other materials used in orthopeadic implants, Si3N4 shouldnt accumulate in the body as it can be excreted. Meanwhile Titanium, Trabecular Metal, PEEK, ZTA, all accumulate in the tissue, blood and/or organs. Metals seem to spread through the body while other ceramics and plastics mostly accumulate locally. This is all important to understand when you consider that Si3n4 is destined to replace current materials used in the $64 billion ortho implant industry. As Si3n4 can be used as a coating for metal implants and can be imbued in PEEK materials, it could and should capture almost the entire ortho industry but only with partnerships.
Markets Si3n4 can be used in (not comprehensive and only represents the medical/antipathogenic side of its uses)
Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Total = $276.88bn
Its honestly overwhelming the size of the markets Sintx material can be used in. Hypthetical scenario using 5% market penetration with a 5% licensing fee equates to $692m in yearly revenue. Thus Si3N4 is worth at least $700m in potential yearly revenue for an acquiring company through licensing revenue.
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Sources:
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/22/orthopedics-market-set-to-reach-64bn-by-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
========================================
Joe, i guess you didnt specifically deny that there was a hostile party shorting Sintx and trying to secretly acquire a position to seize board seats and take the company. However what you did do was appeal to ridicule. Style my hypothesis as being ridiculous.
You claim to be against these sorts of vulture funds yet your every post is against Sintx/management and therefore in support of those vultures trying to acquire Sintx IP cheap.
Oops, almost forgot. Another buying opportunity! Get in before phantom ready-to-steal man is revealed (but can't...thanks poison pill) and Sint is sold for trillions. Sonny has had your backs all along....just shutup and keep buying.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170308414
Sonny's poison pill will stop Musk from taking over and thus save the day for present shareholders.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170393544
Appeal to ridicule (also called appeal to mockery, ad absurdo, or the horse laugh) is an informal fallacy which presents an opponent's argument as absurd, ridiculous, or humorous, and therefore not worthy of serious consideration.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
boston745
6 days ago
Their playbook is simple: they find a promising company like Nano that has attracted significant investment, furtively acquire a large position, and then seek to dismantle the company and distribute its cash for Defendants’ own benefit
This quote from the lawsuit indicates that Ansons group of funds target promising companies, even if poorly managed, with attractive assets. This isnt simply about exploiting a situation and profiting from shorting. This is targeted to go after, in Sintx case, very valuable IP. Interestingly with Sintx 3D printing foray, Nano could be a nice fight if Ansons group of funds got both companies IP. I suspect these hedge funds are working as a front for another company but i have not seen any evidence to prove that. Like is the group of funds connected at all to Renaissance which is directly tied to J&J?
They acquire positions collectively so as to stay under 5% to avoid disclosure rules. I had previously said that i thought Sonny was utilizing shareholder rights offerings to prevent such action which again you denied was happening. As i already said, it looks like their last play is to keep SINT valued so low management isnt able to raise funds. Fortunately Sintx has like no debt. Sonny could always auction IP for significant gain for current shareholders if he cannot find ways to secure funding. As CTL is setup for crown jewel defense more likely CTL buys the IP cheap and yes shareholder always lose out in this battles like this.
Nano isnt a small penny stock company either, its market value is over $400m and fast growing revenue.
2. Defendants are a consortium of hedge fund short-sellers who conspired to obtain a large stake in Nano by working in tandem to lower the price of the company’s public securities in order to buy them for themselves. Their playbook is simple: they find a promising company like Nano that has attracted significant investment, furtively acquire a large position, and then seek to dismantle the company and distribute its cash for Defendants’ own benefit. Such conduct violates numerous securities and legal strictures and has caused Defendants to be named as defendants in actions brought by the U.S. Securities and Exchange Commission and other government and private organizations.
4. Beginning in 2022, Defendants began targeting Nano by manipulating the price and market for Nano ADSs, acquiring a large undisclosed interest, and ultimately mounting a bid for control. They did so in violation of SEC regulations that require investors (or coordinated groups of investors) to disclose when they acquire beneficial ownership of 5% or more of a company’s shares. The regulations exist to protect other investors and the issuers from stock price manipulation and creeping takeover attempts. Defendants failed to make the disclosures in order to avoid regulatory and investor scrutiny. Defendants then attempted to use their newly-acquired ownership of Nano securities to raid the company.
driving down Nano’s share price so that Defendants could acquire even more shares at artificially reduced prices. Defendants again violated U.S. securities law disclosures designed precisely to alert the market to such activity. Defendants ultimately acquired cumulative ownership interests in Nano above 10% and continue to seek to overthrow the company’s Board and wrest control from its managers.
One more thing is this group of funds have been accused of interfering with loans and customer bases to get what they want. Meaning even if management is "good", their tactics are so underhanded they can depress most companies that do not have the resources to fight back.
https://www.sec.gov/Archives/edgar/data/1491072/000119312523131774/d264274dex993.htm
joev2
6 days ago
I am not in the least, defending those like Anson. I despise these types BUT I DO understand their taking advantage, BECAUSE a company is run so poorly. I mentioned in another post that whatever 'illegal' involvement there may be, you can forget the powers that be, from taking action. That's NOT downplaying lousy behavior. What I'm doing is putting the EMPHASIS on the Sints of the world, WHICH make the antics of the Anson types, all too possible and easy. I'm pointing out an evident cause and effect; something you do not do. Btw, I put Maxim in there as well, as I do, Ascendiant (companies Sint does 'business' with). They too wouldn't have such lucrative businesses IF Sint types weren't out there, helping them along with their own stupidity, naivety and in some cases, corruption.
boston745
6 days ago
You continue to downplay these funds actions. Why do you attack Sintx yet defend the funds like the Ansons of the world who you claim are simply exposing these companies fraudulent behavior not as publicly claimed, manipulating companies for profit as shown below? Your previous post you indicated that I somehow conveyed Sintx was the first to experience such things and now youve shifted to ive indicated its special in experiencing this. Well it is special, but not in that this is new behavior for Ansons family of hedge funds. Theyve done this before and will again.
Anson Funds and Murchison’s Dirty Partnership – Another Lawsuit: Nano Dimension
UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK
NANO DIMENSION LTD.,
Plaintiff,
v.
MURCHINSON LTD., EOM MANAGEMENT
LTD., NOMIS BAY LTD., BPY LIMITED,
ANSON ADVISORS INC., ANSON FUNDS
MANAGEMENT LP, ANSON MANAGEMENT
GP LLC, BOOTHBAY FUND MANAGEMENT,
LLC, BOOTHBAY ABSOLUTE RETURN
STRATEGIES, LP and BOOTHBAY
DIVERSIFIED ALPHA MASTER FUND, LP,
2. Defendants are a consortium of hedge fund short-sellers who conspired to obtain a large stake in Nano by working in tandem to lower the price of the company’s public securities in order to buy them for themselves. Their playbook is simple: they find a promising company like Nano that has attracted significant investment, furtively acquire a large position, and then seek to dismantle the company and distribute its cash for Defendants’ own benefit. Such conduct violates numerous securities and legal strictures and has caused Defendants to be named as defendants in actions brought by the U.S. Securities and Exchange Commission and other government and private organizations.
4. Beginning in 2022, Defendants began targeting Nano by manipulating the price and market for Nano ADSs, acquiring a large undisclosed interest, and ultimately mounting a bid for control. They did so in violation of SEC regulations that require investors (or coordinated groups of investors) to disclose when they acquire beneficial ownership of 5% or more of a company’s shares. The regulations exist to protect other investors and the issuers from stock price manipulation and creeping takeover attempts. Defendants failed to make the disclosures in order to avoid regulatory and investor scrutiny. Defendants then attempted to use their newly-acquired ownership of Nano securities to raid the company.
Thats funny because i thought that Sonny executed shareholder rights offerings, which can be used like poison pills, to prevent such things from occurring. Notice how in this case these funds collectively acquired a significant stake in the company without triggering sec disclosure. Now it seems this group is trying to drive the price so low that Sintx cannot raise much to keep funding development. This could explain why Sintx has engaged Ascendiant to help it secure funding in different ways and why Ascendiant is now under attack.
Fast Fact
Poison pills are formally known as shareholder rights plans.
That's what I thought and exactly what I argued last year. Which means either Dr. Bal is paranoid or there is a shark out there that doesnt want its intentions known.
Look at that, i posted this Jun 2023 and there definitely does seem to be a shark out there that doesnt want its intentions known! Which again makes me wonder if Maxim was part of this all along as i doubt it wasnt aware that Ansons family of funds work together.
Quote Sources:
https://marketfrauds.to/anson-funds-new-lawsuit/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172155709
https://www.investopedia.com/terms/s/scorchedearthpolicy.asp
========================================
A conspiracy of shorting and distorting.
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
========================================
The Value being created at Sintx can be seen in the following posts and links:
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883
========================================
Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281
========================================
Silicon Nitride = Next Gen Hip Implant Material
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
========================================
Electromagnetic fields, metal implant corrosion, and dis-ease it causes
https://i.imgur.com/nLg7SXT.jpg
Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/
Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
joev2
6 days ago
I guess I'm one of the "you guys". Let me again be clear as to what I've always said. I cannot prove one way or the other how much or how little things are manipulated concerning stock prices. Sonny's dealings or non-dealings with Zimmer have never concerned me much. Why? Because my firm belief IS and has always been that this company is not investment material. I base that MOSTLY or possibly EXCLUSIVELY on Sonny's handling the CEO position, especially in regards to announcements that don't quite pan out, such as O2 and hey, we're fine financially....only to go majorly to the well not that long afterwards. Tells me, he doesn't understand how to run a public company and probably ANY company IF the desire is to raise cash and investment interest. He turns any TRUE investor off and the Ansons and Maxims on. In my mind, it's quite simple. You run a company like a jerk, other jerks make a jerk out of you. Or if you prefer, expose the jerk you are.
Re my comment about Sint not being the first to go this route: it was meant to show that ALL clown shows pay a similar price, not just Sint. THIS is what you call disinfo or misinfo, but it isn't. EVERY company I've seen run it's shop in similar fashion to Sint, meaning they APPEAR clueless, gets taken advantage of. Sint is and was no different. Otoh, you have often made it sound as if a "special" conspiracy has been launched against Sint. I couldn't disagree more! I've seen it all too often.
boston745
6 days ago
Of all what i posted thats the only thing you take issue with? Guess that means you agree with the rest. Let me expand on what i was saying as i didnt mean Sonny is literally watching ihub. Companies routinely have employees that check social media boards and i have found that some of that information get passed upward. Like when i posted the 30 year study out of Australia on implanted Silicon Nitride spinal implants that were implanted before Sintx founding. As far as i know Sonny wasnt aware of that study until i posted it here but he referenced that study after i posted it here on a later a conference call i believe. Same thing has happened on the Teslas board. Musk has actually posted or said things that appear to be associated with something i posted on that board beforehand. Do i think Musk read what i posted? No. I think word got to him though. Outside of that im nobody, just a messenger.
========================================
Someone on cafepharma is claiming that Dr ZB got inside info from CTL but it looks more likely that he got it from Anson's family of funds because Dr ZB is a cardio surgeon not a spinal surgeon. Tenax drug shows promise in being used for cardio surgeries so who better to provide insight/consulting services than a cario surgeon? Thus its more likely he passed info to Hudson Bay, et al and they told him about SINT than Chon told Dr. ZB about SINT. As i said already, all four companies Dr ZB invested in over a 1 year period, were companies that Hudson Bay or any of the Anson family of funds were/have invested in.
Levosimendan has also been studied in other therapeutic applications, particularly cardiac surgery - in which it has shown a range of beneficial haemodynamic and cardioprotective effects, and a favourable influence on clinical outcomes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868185/
========================================
I dont know where you get the idea ive claimed or think that Sintx is the first to go down this road?
You guys claimed Zimmer Biomet wasnt their strategic partner, i proved it was.
You guys claimed there was no short and distort conspiracy here, i proved there has been.
Ive claimed that Tesla is a fake it until it makes it scam and now its under investigation for that sort of behavior.
Ive shown flying saucers are in fact manmade first designed by Viktor Schauberger in the 1930s.
Ive even shown the reason that 9/11 was a false flag (So the US could leave the 1972 ABM treaty). - Fixed to reflect the correct year.
The real losers ARE always those who believed and invested.
That just depends how things move forward and how this story ends. Sintx has a shit ton of value not reflected by the markets. Heck its $270m shareholder deficit is worth alot to an an acquiring company, least 200m, before factoring in the IP has over 240 billion addressable markets in can sell into and significant partnerships hidden behind NDAs. Those that lose are those that give up. Im not going anywhere.
========================================
Heres 4 markets Sintx can participate in to give an idea of potential worth. Mind you Sintx can play in more markets than this:
Global Ortho device market = $64bn by 2025
Global Catheter market = $55bn in 2023
Personal Protective Equipment market = $79.53 billion
Antibacterial market = $44.5bn 2024
Right there thats a maximum of $243bn in just 4 markets. This doesnt include Dental implant market, Wound Care market, Oncology market via Cancer treatment applications and so many other markets Sintx could participate in. Hell im surprised Musks Neuralink hasnt tapped Sintx as the material would help with implantation both in reducing infection as well as reducing toxic corrosion.
People may look at this and think its ridiculous because Sintx is worth like 4.2m but its material is destined to replace current biomaterials in the ortho market. Its antiviral, antibacterial, antifungal so great product for catheter and PPE markets. Assuming it can be imbued in soap solutions obviously it would be great for the antibacterial markets as well. Its shows effectiveness against all ss-RNA viruses including Bird Flu & Covid. As well as they found its effective against herpes which is a double stranded DNA virus meaning it could be effective for the 10b condom market to help slow the spread of STIs.
Instantaneous Inactivation of Herpes Simplex Virus by Silicon Nitride Bioceramics
https://www.mdpi.com/1422-0067/24/16/12657
boston745
7 days ago
Do i stop it? No. Only thing i can do is shine a light on the problem and Sonny or any others watching can do what they will with the information. My post about Dr ZB is more about how these funds work and i believe helped create an aura of trading as to cover the insider trading, than Dr Binsalamah himself.
I dont know where you get the idea ive claimed or think that Sintx is the first to go down this road?
You guys claimed Zimmer Biomet wasnt their strategic partner, i proved it was.
You guys claimed there was no short and distort conspiracy here, i proved there has been.
Ive claimed that Tesla is a fake it until it makes it scam and now its under investigation for that sort of behavior.
Ive shown flying saucers are in fact manmade first designed by Viktor Schauberger in the 1930s.
Ive even shown the reason that 9/11 was a false flag (So the US could leave the 1973 ABM treaty).
The real losers ARE always those who believed and invested.
That just depends how things move forward and how this story ends. Sintx has a shit ton of value not reflected by the markets. Heck its $270m shareholder deficit is worth alot to an an acquiring company, least 200m, before factoring in the IP has over 240 billion addressable markets in can sell into and significant partnerships hidden behind NDAs. Those that lose are those that give up. Im not going anywhere.
========================================
Heres 4 markets Sintx can participate in to give an idea of potential worth. Mind you Sintx can play in more markets than this:
Global Ortho device market = $64bn by 2025
Global Catheter market = $55bn in 2023
Personal Protective Equipment market = $79.53 billion
Antibacterial market = $44.5bn 2024
Right there thats a maximum of $243bn in just 4 markets. This doesnt include Dental implant market, Wound Care market, Oncology market via Cancer treatment applications and so many other markets Sintx could participate in. Hell im surprised Musks Neuralink hasnt tapped Sintx as the material would help with implantation both in reducing infection as well as reducing toxic corrosion.
People may look at this and think its ridiculous because Sintx is worth like 4.2m but its material is destined to replace current biomaterials in the ortho market. Its antiviral, antibacterial, antifungal so great product for catheter and PPE markets. Assuming it can be imbued in soap solutions obviously it would be great for the antibacterial markets as well. Its shows effectiveness against all ss-RNA viruses including Bird Flu & Covid. As well as they found its effective against herpes which is a double stranded DNA virus meaning it could be effective for the 10b condom market to help slow the spread of STIs.
Instantaneous Inactivation of Herpes Simplex Virus by Silicon Nitride Bioceramics
https://www.mdpi.com/1422-0067/24/16/12657
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
A conspiracy of shorting and distorting.
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
joev2
1 week ago
Boston, even if you're 100% correct, how do you stop it? Do you think Bal and co. are the first to go down in this cesspool of never ending shorting games, reverse splits and offerings? Like I said, these guys are professional vultures and they take advantage of every unsuspecting startup; not to mention those who willingly go along with them. The real losers ARE always those who believed and invested.
A real culprit in all of this is the SEC who despite making billions on fines, can't seem to ever get the right personnel (or laws) to finally stop this crap. What we need is Congress to pass laws that work! Oops, almost forgot...they benefit as well, by keeping things just the way they are.
boston745
1 week ago
Looking into the matter of inside trading i have uncovered the following:
Dr Ziyad Binsalamah is a Thoracic Surgeon (Cardiothoracic Vascular Surgery) that was practicing in Houston Texas at the time. One of Anson's funds is located in Houston area.
Hudson bay files a 13G in Tenax Feb 2019.
March 2019 Tenax reveals that it has begun phase 2 trial of its drug
May 2019 Dr Binsalamah begins investing in Bridgeline Digital
August 2019 Tenax provides business update revealing top line data Q1, 2020
April 2020 Tenax provides update that its topline data is due late June 2020
Dr. Binsalamah buys shares May 2020. Sells when the price pumps on topline data release June 2nd.
Same day he sells Tenax he buys SINT for which he sells SINT on its price pump June 22nd.
July 2020 Dr Binsalamah begins buying Interspace Biosciences for which he closes his position August 2020 about a month later for a 30-40% loss.
Dr Binsalamah has not filed further 13Gs since.
My interpretation of the above information suggests that Hudson Bay or any of its family of funds contacted Dr Binsalamah to provide consulting services and possibly keep track of trial progress; trial was not at a Hospital in Texas so its not likely Dr Binsalamah had direct access to data. Being a Cardio surgeon he could befriend or associate with the doctors using the drug at one or more of the 10 hospitals. In exchange, it seems, Dr Binsalamah would be given information to profit from trades. To accomplish this without raising red flags he traded four companies that were all associated with Hudson Bay. First was Bridgeline Digital for which he traded for a year. This company i believe was to establish his trading profile. Then he did two quick trades in Tenax and SINT for large profits. Under this hypothesis this represents the core of his compensation for information/consulting services. His final trade was in Interspace Biosciences where he traded over a month and seemingly took a loss...assuming he wasnt short in another account. Since these 3 of these trades were all short lived it could raise red flags for insider trading. Thus by taking a loss in his Interspace investment, it helps provide cover. I contend all three trades outside of Tenax were meant to help establish Dr Binsalamah as a trader and help cover inside information he may have had from contacting Doctors associated with Tenax trial. As all four funds are associated with Hudson Bay and Ansons family of funds, it looks like an exchange of information was done. I do not see any reason for Dr. Binsalamah to be associated with Sintx.
Data source:
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=005-58467&type=&dateb=&owner=include&start=0&count=40
https://clinicaltrials.gov/study/NCT03541603#contacts-and-locations
https://investors.tenaxthera.com/news
https://sec.report/CIK/0001783976
========================================
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
========================================
The Value being created at Sintx can be seen in the following posts and links:
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
boston745
1 week ago
In light of the recent revelation that there has been a conspiracy of funds shorting and distorting SINT/AMDA since 2015, the following information suggests that these funds were still in the background in 2020 when Dr Ziyad Binsalamah invested for the 2020 pump. The fact that Dr Binsalamah was invested for the duration of the pump, just before it began, suggests he was given inside information. Informational compensation for services or information given? Did Dr. Binsalamah give out some inside information to Anson family of funds? I am curious how Dr. Binsalamah is connected Ansons family of funds which Hudson Bay Capital is but one? I originally posted this in 2022. I suspect alot of compensation to those associated with pumping and dumping/shorting & distorting are compensated with information they can make alot of money with rather than traditional payments.
All 4 of the stocks Dr ZB invested in were or are associated with Hudson Bay Capital, a known vulture fund. My guess is hes an associate of that fund, maybe part of the pump and dump scheme they run. 2 of the 4 he shows up for under a month for a pump and dump. Sintx & Tenax which had good phase 2 outcome. There's no way every company he happens to jump into is or was associated with Hudson Bay. Just so happens, Hudson Bay was one of the funds from 2015 that held shares in Amedica now Sintx.
Sintx:
Only four funds among those we track were long Amedica Corporation (NASDAQ:AMDA) at the end of 2015. Among them was Sander Gerber’s Hudson Bay Capital Management, which declared holding 3.77 million shares worth $423,000 as of December 31. It should be noted that following a 1:15 reverse stock split in January, Hudson Bay’s stake should amount to roughly 251,131 shares now.
https://www.insidermonkey.com/blog/why-disney-dis-amedica-amda-cvent-cvt-unipixel-unxl-and-repros-therapeutics-rprx-are-spiking-today-444128/
Tenax
https://www.sec.gov/Archives/edgar/data/1378590/000139382519000047/0001393825-19-000047-index.htm
Bridgeline
https://www.sec.gov/Archives/edgar/data/34956/000139382519000103/0001393825-19-000103-index.htm
Interpace Biosciences
https://www.sec.gov/Archives/edgar/data/1054102/000143774917005108/idxg20170322_8k.htm
Hudson Bay Capital Management is a fund that has previously settled SEC charges for securities laws violations and has been linked to an ongoing investigation relating to an alleged pump and dump ring.
https://utopiacap.com/hudson-bay-capital-management/
Binsalamah Ziyad
SEC CIK #0001783976
https://sec.report/CIK/0001783976
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170339659
boston745
1 week ago
Noneya, you arent all about the truth but i will give you that you do use the truth the most of those bashing Sintx. However you do tend to use truth to tell lies, use implication to give wrong impression, and other methods of distortion which you put under the umbrella of "sarcasm". Your posts about where are these products is factual but purposefully misleading. If your intent is not to mislead then i suggest the word "When". When are these products going to be commercialized not where are they which implies they failed or not forthcoming one day. If you are really curious about products like wound care please look at their recent presentation and 10k filing. Ive linked them for you.
https://ir.sintx.com/company-information/presentations
We have several partnerships exploring opportunities in face masks, filters, wound care, and coatings.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm pg 10
LMFAO - Long Term Agreement for
$250,000 a YEAR Estimated.
AND FAILS TO SAY THAT THEIR FURNACES FAILED.
So CAN'T MAKE CHIT
Why is noneya using truth to mislead? Noneya i thought you were all about facts? Its the armor furnace that failed is it not, which is a subsidiary? That has nothing to do with their ability to produce non-armor based aerospace (jet engine components) or medical products. Here again you've used truth but did so in a way that implies they could not produce the items needed to fulfill the LTA. Although you added S to furnace which is a lie indicating more than one furnace failed. Only one furnace failure was disclosed so either you lied or have information no one else has access to.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173360835
========================================
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
========================================
The Value being created at Sintx can be seen in the following posts and links:
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
XenaLives
1 week ago
Repost - see replied to post:
This is essentially how the Anson family of funds (is Anson at the top of this family?) work SINT and its offerings.
Here is a trade that is almost guaranteed to make money, though it is also double super illegal.
These companies -- there were 13 of them, all pretty small -- raised money through what the SEC calls "confidentially marketed public offerings." A company would engage an investment bank, which would call up potential investors and ask if they wanted to buy shares in the company. The bank would do this before the company publicly announced the offering, and would "wall-cross" the potential investors, making them agree to keep the information about the offering secret until it was announced publicly.
So here's a predictable stock-market pattern and an easy way to exploit it: If a company calls you up to ask you to invest in its upcoming public offering, you should (1) say yes, (2) sell the company's stock short before the public announcement, and then (3) buy the stock back in the public offering, generally at a 10+ percent discount, a few days later.
This is of course not legal advice! It is a great trade, but it is also double super illegal, insofar as:
There is a specific SEC rule against short selling stock just before a public offering and then buying back the stock in the offering, 5 and
There is a general, and much more important, rule against trading on purloined material nonpublic information, and this is that.
trading in breach of that agreement, you are clearly violating not just the contract, but also insider trading laws, which make it illegal to trade "in breach of a fiduciary duty or other relationship of trust and confidence, while in possession of material, nonpublic information about the security."
But, you know, who will check?
Some of the funds would get wall-crossed, and then they'd tip each other and trade in the other funds to try to obscure what was going on:
When they were successful in obtaining such information, Fishoff shorted the issuer’s stock in advance of the offerings, directed trading by Chernin and Costantin in those instances when he did not place the trades on his own, and tipped Petrello, who then also shorted the stock through Brielle and Oceanview.
In many instances, the Fishoff-controlled entities for which Chernin and Costantin were fronting also participated in the offering, with the stock going to Featherwood’s account and often being used to cover the short sales.
This right here is most likely how this family of funds worked. 1+ of them would get information of a forthcoming offering which it would later participate in, and tip the others off so they can pre-short. Not sure why the author says pre-short, wouldnt this be naked shorting? They then used the shares from the offering that Fund #1 received to cover those naked short positions?
By cheating on their wall-cross agreements and shorting the stock, these guys had the effect of driving down the stock price, which probably reduced the price in the offering. These companies probably got less money for their stock because their nonpublic information was (allegedly) used against them.
Joe, this next part does have merit here and could support what you've claimed about management and the board.
Though you could have a more cynical view of this sort of thing. A company needs to sell stock, but worries that announcing a public offering will drive down its stock price and not produce any takers. So it calls some investors up privately and tells them it's doing a deal. Those investors agree to invest in the deal, but before the deal is announced they lay off their risk by shorting the company's stock. Then the deal is announced and the investors buy shares from the company to (illegally) cover their shorts. The investors get their 10 percent, or whatever, discount to the market price as a commission; their real function is not to invest in the deal but to intermediate between the company (which can't sell stock without a publicly disclosed offering) and the unsuspecting public (which buys from the "investors" before the public disclosure). The wall-cross agreement creates deniability for the company. No one's stealing from the company; they're helping the company get a deal done that would otherwise be much harder to achieve. The victims are the public who buy from the insider traders at the inflated, pre-announcement price.
There is definitely evidence supporting this, especially between 2022 RS & 2024 RS. For instance, Lind Group participated in the offering at .25 and per our discussions Joe, funds naked shorted from as high as .50s before Lind used their shares to cover those shorts at .15. Thus this group of funds "laid off their risk", making millions in a few days, and did in fact work as an intermediary between the company and the public as they dumped shares. Lind Group sold off its shares in a matter of days. This group of investors gets a hell of alot more than 10% off these offerings. After factoring in the 200:1 split theyve been shorting since 100 with a hell of a pump and dump between .04 to .22 pre-split (8-44 post split).
https://web.archive.org/web/20190331202955/https://www.bloomberg.com/opinion/articles/2015-06-03/insider-traders-made-some-easy-money-on-stock-offerings
Something Xena posted years ago here and it seems to correlate with all this, especially post split as theyve been walking the price down.
The 10000 can be wash traded back and forth freely between colluding computers. Tons of money is made so they can now walk the stock down even lower because risk has been reduced.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139777542
That seems to correlate with this wash trading where funds can increase (decrease) the price with this action.
How To Run a Pyramid Scheme — But On The Stock Market
https://www.reddit.com/r/wallstreetbets/
XenaLives
1 week ago
Repost, see replied to post:
Things just go SOOOO much more interesting with this revelation. It shows there has in fact been a conspiracy of funds, shorting and distorting Sint & Sintx since 2015. My next post will give some insight into how this family of funds might operate. This includes shorting before offerings exactly as ive said was occurring but it looks like the other funds do the shorting and then cover with the shares the fund that bought the offering received. Also seems to include wash trading back n forth just like Xenalives has posted in the past.
Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.
List of potential investors the Plaintiff was referencing. All the funds that seem to be connected are in red.
List named the following:
• Anson Funds Management LP and its affiliates
• Ayrton Capital, Altos Opportunity Fund and their
affiliates
• Crede Capital Group, Acquitas Capital and its affiliates
• CVI Investment, Heights Management, SIG and their
affiliates
• Connective Capital and its affiliates
• Empery Asset Management and its affiliates
• Intracoastal Capital LP and its affiliates
• Hudson Bay Capital Management and its affiliates
• Ionic Venture LLC and its affiliates
• Lind Partners and its affiliates
• Li Capital Global Opportunities Master Fund and their
affiliates
• Sabby Management LLC and its affiliates
Source of this list:
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf
List of Funds that have had stakes in AMDA/SINT at one time or another. You'll notice that 3 of the family of funds bought recent offerings of Sintx.
4/01/2024 L1 Capital Global Opportunities Master Fund, Ltd.
https://www.sec.gov/Archives/edgar/data/1269026/000107997324000472/0001079973-24-000472-index.htm
2024-05-14 13F Anson Funds Management LP 959,297 47
https://fintel.io/so/us/sint
2/07/24 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963824000396/0000929638-24-000396-index.htm
2/16/2023 INTRACOASTAL CAPITAL, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000121390023012455/0001213900-23-012455-index.htm
2/14/2023 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963823000614/0000929638-23-000614-index.htm
05/18/2018 CVI Investments, Inc.
https://www.sec.gov/Archives/edgar/data/1269026/000110465918034362/0001104659-18-034362-index.htm
01/19/2017 SABBY MANAGEMENT, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000153561017000068/0001535610-17-000068-index.htm
07/14/2016 ALPHA CAPITAL ANSTALT
https://www.sec.gov/Archives/edgar/data/1269026/000121390016014963/0001213900-16-014963-index.htm
9/14/2015 Frigate Ventures LP = Anson Group
This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Frigate Ventures LP (d/b/a Anson Group), a Texas limited partnership (“Frigate”), Admiralty Advisors LLC, a Texas limited liability company (“Admiralty”), Mr. Bruce R. Winson, the principal of Frigate and Admiralty, M5V Advisors Inc. (d/b/a Anson Group Canada), an Ontario, Canada corporation (“M5V”), Mr. Adam Spears, a director of M5V, and Mr. Moez Kassam, a director of M5V, relating to Common Stock, $.01 par value (the “Common Stock”), of Amedica Corporation, a Delaware corporation (the “Issuer”).
https://www.sec.gov/Archives/edgar/data/1269026/000119312515319457/0001193125-15-319457-index.htm
Hudson Bay Capital Management LP 2,789,867 2.16 870,438 Sep 30, 2015
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118775462
XenaLives connecting CVI to ALPHA CAPITAL ANSTALT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143618825
boston745
1 week ago
SINTX VP of R&D, Dr. Ryan Bock, and Associate Scientist, Ms. Tabitha Derr, participated in the 2024 Implant Polymers UHMWPE & PEEK Conference in Barcelona, Spain, June 20-21. This conference, organized by SINTX collaborator Prof. Steve Kurtz of the Drexel Implant Research Core, is the premier meeting for discussing developments related to PEEK implantology, including composites and additive manufacturing. Ms. Derr presented a poster and delivered a short talk on her work related SINTX’s NIH-funded additively manufactured SN-PEKK CMF implant project, while Dr. Bock communicated a podium presentation describing the benefits of silicon nitride as a composite constituent and highlighted its inclusion in additively manufactured SN-PEEK spinal implants and SN-coated additively manufactured carbon fiber reinforced trauma plates as part of two NIH-funded development programs.
biennial conference brings together major material suppliers, printer manufacturers, and academicians in this space, which allowed us to catch up in person with all of our current collaborators and forge new relationships over a very busy two days.
https://www.linkedin.com/posts/sintx_sintx-vp-of-rd-dr-ryan-bock-and-associate-activity-7210995210334478336-SLfG
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883
========================================
Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281
========================================
Silicon Nitride = Next Gen Hip Implant Material
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
========================================
Electromagnetic fields, metal implant corrosion, and dis-ease it causes
https://i.imgur.com/nLg7SXT.jpg
Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/
Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
boston745
1 week ago
Bird flu map shows unprecedented spread as expert warns future pandemic inevitable
The Centers for Disease Control and Prevention says the risk to the general public is “low” but it is “watching the situation carefully and working with states to monitor people with animal exposures.”
Since 2022 there have been four reported human cases, the most recent three - all this year - following exposure to infected dairy cows. The risk is tempered by the fact that it doesn’t spread easily among humans.
But public health officials fear that could change. Just recently former CDC director Dr Robert Redfield told NewsNation: “I really do think it’s very likely that we will, at some time, it’s not a question of if, it’s more of a question of when we will have a bird flu pandemic.”
And writing in the New York Times, Dr Jennifer B Nuzzo, an epidemiologist and director of the Pandemic Center at the Brown University School of Public Health, warned that the virus “could mutate to gain the ability to infect people more easily.”
That would “likely cause a new pandemic.” With the disease proving fatal in around half of the nearly 900 people known to have contracted the H5N1 strain of the virus worldwide since 2003, bird flu is “typically more dangerous than the viruses that cause seasonal flu and COVID-19.”
Meanwhile, outbreaks of H5N1 have been detected in 525 counties and 48 states. The CDC says almost 97 million birds have been affected since January 2022 when the first H5 viruses to be found in the US since 2016 were detected.
The virus has also spread to 92 dairy cow herds in 12 US states.
Another pandemic wouldnt help Sintx and Cardinal Health sell some PPE products and capture some of that market im sure.
These PPE products need to already been on market before bird flu turns into an actual pandemic. The infection kill rate is 50% so far which is really really bad.
https://sintx.com/applications/antipathogenic/
https://www.the-express.com/news/us-news/141099/bird-flu-outbreak-map-pandemic
========================================
Meanwhile there has been a conspiracy of hedge funds shorting and distorting Sintx/SINT/AMDA since 2015 that anyone can verify. Isnt it funny TA that your account appeared at the same time as Anson's family of funds and that you consistently post blatant lies on ST? The only thing you dont seem to lie about is the stock going down which you seem to help make sure happens with your deceptive posts.
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
boston745
2 weeks ago
AMDA you also said explore for alternative which implies they have to go looking for something, in desperation, instead of exploring options that might already be on the table. Yes they could have options already on the table with strategic partners. Youre purposefully changing what was said regardless if you work in tandem with Ansons conspiracy of funds or not. Something you also claimed wasnt going on. Evidence shows otherwise.
You guys keep acting like im crazy despite the evidence showing otherwise. Evidence shows the medical device market is 64b in size and that Sintx Silicon Nitride is destined to one day replace current biomaterials. If it has the partners why couldnt this be true? Catheter market is apparently 55bn in size with significant problems related to both bacterial and fungal issues for which a Si3N4 coating could help prevent. Again why wouldnt Sintx Silicon Nitride not capture a large share of both of these markets if the product does what scientific studies shows it can do? Im not claiming Sintx can do it by itself but utilize the strategic partnerships it already has in place. What am I missing? Sonny is patenting the tech like crazy for a reason. 150 freaking patents pending worldwide. That seems like alot of patents for tech that cant do whats claimed.
Their collaborative study is the first to show how the fungus Candida albicans infects the catheterized bladder. Fungal infections are difficult to treat and represent a significant and growing public health concern around the world.
Catheter-related blood circulation infection is the most dangerous and serious side-effects of vascular catheters, which leads to the enhancement of the costs, mortality, and hospital stay duration, especially in the Intensive Care Unit.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
boston745
2 weeks ago
Tisk Tisk AMDA. Here is evidence of distorting the facts, part of the short and distort campaign here:
the disturbing part is that they have to "explore" for alternatives. according to that boston guy, the hidden value here is so great that you would think potential partners/suitors would be beating down Sonny's door - not the other way around. there is total denial/insanity in New England....
First off nowhere does the word "alternatives" appear in the press release. The title of the press release states that they are exploring strategic options. IE the options that may already be available to them and they are seeing if those options are worth it; engaging Ascendiant is to help with valuation and negotiations. Which as ive stated already, theres an option with NP Aerospace for armor or any of its strategic partnerships to take a stake in Sintx. According one site, the company announcing this exploration publicly can enhance or increase the value potential of those options. As Sintx has multiple strategic partners it could also increase the number of joint ventures. The first through the door gets the best deal and thus i see NP Aerospace as likely candidate who could really benefit by such a venture at current way undervalued state SINT is in. Snowball running down the hill effect. However these things take time.
“With technologies targeted at the medical, defense, and renewable energy markets, year-over-year growth in revenues, and other commercial opportunities in the pipeline, SINTX will require additional investment and resources. As such, we want to examine all strategic opportunities targeted at maximizing shareholder value,” said Sonny Bal, Chief Executive Officer and Chairman of SINTX. “We believe that potential partners will find significant value in SINTX’s businesses and capabilities.”
This specific paragraph suggests that what they are looking for is one of their strategic partners to take a stake in Sintx which will help fund R&D of products between the companies. Possible joint venture between Sintx and one of its strategic partners. The fact that the stock price didnt skyrocket on this news is good as it means that the opportunity is likely. If they can secure a joint venture it could mean an end to public offerings. They could do private placement offerings, rights offerings, & loans. Hopefully limiting any debt. That doesnt prevent public offerings before such a deal. This also depends on the size of the partner. NP Aerospace is a small company which if it took a stake would limit the value of such a stake.
Just to clarify, Sintx partners not beating down the doors is strategic for them. They make too much noise too early it'll cost them. Also it depends on what stage the co-developed products are in development as to when they'd be comfortable stepping up. Once this snowball gets running with big players...
Quote Sources:
https://stocktwits.com/amda/message/577330876
https://sites.duke.edu/thefinregblog/2021/06/10/should-a-company-reveal-that-it-is-evaluating-strategic-alternatives/
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
boston745
2 weeks ago
243b x .05 market penetration x .05 licensing fee = $607m a year revenue. You dont think $607m revenue is easily worth paying $1.2b for? This said i expect Si3n4 to penetrate into those markets more than simply 5%. Specifically the Catheter and Ortho markets where it should extensively capture because it can be coated and imbued on current materials if not replace them entirely while bringing its antipathogenic properties and increased bone cell stimulation or osteointegration to those products. Because Si3n4 is anti all pathogens it could easily capture much larger share than 5% of the antibacterial market but i havent seen the scientific data of how effective Si3N4 is added to these soaps. As Si3N4 is soluble it does break down overtime. Which could be a good or bad thing. Does it retain its ability to kill pathogens is the key for the antibacterial market?
In addition to Zimmer Biomet former CEO being the current CEO of Solventum with knowledge of Si3N4, Sintx also hired a VP with connections to 3M before Solventum was spun off. Marcroft also has ties to Medtronic, as does Sonny who consulted for Medtronic in addition to Zimmer, and Boston Scientific. Medtronic should be very interested in Catheters and Si3n4 imbued PEEK products just to name two products. Remember Sintx is a licensing play pure potential play. Even if Zimmer acquires it one day Si3n4 will not be restricted to simply Zimmer's share of the market. Plus thats what Zimmer wants Sintx for, licensing revenue!
https://ir.sintx.com/news-events/press-releases/detail/165/sintx-technologies-appoints-michael-marcroft-as-vice
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
boston745
2 weeks ago
To add to my post about NP Aerospace, here is this part from Tuesdays Press Release.
Other proprietary technologies include the manufacture of high performance, lower cost ballistic materials for opaque armor applications at its subsidiary, SINTX Armor. SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.
This was likely what Sintx and NP Aerospace have been waiting for in regards to some sort of announcement between the two.
========================================
To your so called deflections Joe, my last post specifically indicated that i participated in shareholder rights offering and ive said as much since the 2022 offering. To do so i had to be a shareholder already. I added it after posting that post during the 15min edit window and added it to the wrong paragraph; maybe you just missed it.
Participating in shareholder rights offerings is one way and what i have done.
One thing that would help Sintx/SINT proper valuation is an end to the short and distort campaign thats been waged here for 9 years. It is a fact that there has been extensive shorting and distorting here. Its insanely obvious between the 2022 RS and the 2023 RS with the extent of naked shorting. Every offering over that time included known shorting and distorting fund Anson Group with its family of funds coupled with 50% price declines before and after the offerings. These facts, detailed below.
Another thing that would help with Sintx valuation is management & other Sintx employees finally buying shares after a new shareholder plan is voted on this year. They deserve to reap the rewards of their labor when all those products begin to see the light of day. That coupled with major tutes taking positions. Then for the price to really take off, finally the public announcement of Sintx partnership with Zimmer Biomet as well as partnerships with Solventum & Cardinal Health all with some degree of guidance as to when these strategic partnerships will bring products in the Ortho, PPE, & Catheter industries to market. A sale of Armor division or NP Aerospace partnership certainly wouldnt hurt!
As Sonny is a medical and material research scientist, new CEO to help guide Sintx through all that is a good idea. So him stepping down is the right move if this is going to play out something like i just laid out.
========================================
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
Look at this dated chart and you can see that SINT had been trading in a downward channel but in 2022 price manipulation went to a new level with 50% drops in price before and after each offering. All the while Sintx revenue has been growing as well as its list of collaborations with the military and in the aerospace markets.
https://i.imgur.com/xMRDE8n.jpeg
boston745
2 weeks ago
In regards to this weeks press release, i hope its indication that one of their strategic partners is going to take a stake in the company. Either that or that they will sell the armor division to NP Aerospace.
SINTX Technologies to Explore Strategic Opportunities
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities
NP Aerospace needs a US based manufacturing plant and it uses the exact armor materials that Sintx Armor provides. Donald Bray, Consultant/former VP at Sintx & Morgan Ceramics, oversaw NP Aerospace division before it was divested Nov 2018. 6 months later he was hired at Sintx, April 2019 (6 month non-compete?). This suggests one of the reasons he was brought on, possibly sent, to Sintx was to help Sintx receive ISO 9001 certified facilities so it could produce goods for defense and aerospace applications. IE, supply Morgan Ceramics in Aerospace and NP Aerospace in armor. Morgan Ceramics has been a strategic partner of Sintx since 2016.
NP Aerospace currently has manufacturing locations in England and Canada with only a sales presence in Florida. It could either acquire Sintx armor or simply setup a joint venture. US represents a significant market of interest and target for expansion for NP.
Non-compete
Most states follow the doctrine of “equitable reformation," which enables contracts to be upheld with revisions. For example, a contract that originally lasted five years after an employee's termination may be amended to last for only six months with all other provisions in place.
From NP Aerospace Patent
The outer ceramic armour layer 2 may be segmented armour and may comprise tiles or pellets of ceramic and the ceramic may be of any ballistically suitable type, including without limitation; alumina, silicon carbide, boron carbide, and composite ceramics. Typically the thickness is greater than 4 mm, but thickness depends on threat level.
Sintx Armor currently produces products out of boron carbide and silicon carbide/boron carbide ceramics called Boroshock & Durashock: https://sintx.com/applications/ceramic-armor/
The expansions we are forecasted to see in 2022 are likely to open up some opportunities for us in the long term, to do some really strategic acquisitions in key markets, which in turn will act as a catalyst for faster growth in certain regions. That potential is certainly there for us in the US, which is very exciting,” James concludes.
Quote source:
https://www.freepatentsonline.com/9846013.html
https://manufacturing-today.com/news/np-aerospace/
https://www.legalzoom.com/articles/noncompete-agreements-explained
https://i.imgur.com/slfDxL5.jpeg
https://web.archive.org/web/20221128231656/https://static.seekingalpha.com/uploads/sa_presentations/787/14787/original.pdf
========================================
As you can see Joev2 continues to employ techniques of disinformation in his posts:
https://web.archive.org/web/20231004223836/https://www.ethosdebate.com/lies-rhetoric-4-18-rules-disinformation/
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883
========================================
Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281
========================================
Silicon Nitride = Next Gen Hip Implant Material
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
========================================
Electromagnetic fields, metal implant corrosion, and dis-ease it causes
https://i.imgur.com/nLg7SXT.jpg
Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/
Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
joev2
2 weeks ago
Deflect, deflect, deflect....
Deflection A) Folks, notice there's no comment as to personal involvement in a losing investment, ongoing year after year, yet there remains a continual flow of support for management and supposed value. Why?
Deflection B) attention is drawn to company's alleged billion dollar+ value but NO explanation as to how it can possibly get there under present circumstances i.e. reverse splits, dilution and management being in bed with the vulture crowd all the time.
Deflection C) The usual accusations of distorting and shorting, while ignoring truths as to why the company is and remains in the position it's in, along with the FACT that WHEN investors DO SHORT continually at such a high percentage (as is the case here) they do it because NO ONE CONSIDERS the company a worthwhile investment. This he considers a collusive distort and short campaign.
Truth is folks, people and institutions are just using common sense. If an investor sees a company that's crap, they either ignore it (institutions) or short it (professional shorters and gamers). Showing the smallest of interest as is mentioned frequently here, is nothing more than throwing a buck down on a lottery ticket. Real issue here (always ignored) is WHY doesn't ANYONE invest? Literally NO ONE invests here. That is the point a 'true' believer and investor would want addressed, but would never be by a paid shill. Instead we get accusations and innuendos directed at those who are simply pointing out the obvious. Talk about a distortion campaign lol......
NO ONE WANTS SINT! NO ONE BELIEVES SINT or IN SINT. From management to institutions to accredited lenders to individuals....NO ONE sees true value here and so purported value is made up by an individual based on the purchases of lottery tickets by powerhouse institutions and the like.
boston745
2 weeks ago
Im not going to get pulled into an attempt to create more forum verbiage to drown out good information. Plus im limited to 3 posts a day for going on 9 months now. Yes you've employed a lot of methods of disinformation in your posts. Like TA over on ST, youre good at projecting things you yourself are doing.
When i commented that youve been here for 8 years it means you should know a thing or two about the markets Sintx can participate in. Thus you could give some insight if you wanted as to the potential/value of Sintx Intellectual Property. The fact that you do not want to...is telling. It means you do not want to incriminate yourself or arm me if you agreed; although your original 1-10b spread maybe your attempt at an honest answer. 50b is ridiculous which is likely why you are ok with me saying you believe that. $270m has been spent developing Sintx IP over the years and thus $1.2b represents a decent ROI on that. 10x return would be 2.7b which is about 1% of Sintx addressable markets. However because SINT is so undervalued, those funds can buy super cheap and make back shareholder investment that way allowing SIntx to be acquired for far less than its IP is worth. It'll be interesting if this is how things play out... Still 270m is tax credit offset representing a sizable credit to potential acquiring company. Sintx has a superior/disruptive product that can sell into very large markets and no debt. Thats extremely rare to find at a company worth so little. Thus investors need to protect their investment. Participating in shareholder rights offerings is one way and what i have done.
I completely acknowledge that there is no tute with a large stake in Sintx. This part has evidence supporting it. Having said that, the fact that major funds, mostly connected to Zimmer Biomet, have had small stakes in Sintx for pretty much the entire time we've been here, does not suggest lack of interest as you like to imply. It suggests they are keeping an eye on Sintx but something holds them back (most important funds are Blackrock and Wells Fargo as both are major investors of Zimmer & Biomet before merger). While those funds have been in the background, SINT has been under a short and distort campaign for 9 years now, proof below. As long as those funds & management stay in the background, this short and distort campaign seems likely to continue.
Heres 4 markets Sintx can participate in to give an idea of potential worth. Mind you Sintx can play in more markets than this:
Global Ortho device market = $64bn by 2025
Global Catheter market = $55bn in 2023
Personal Protective Equipment market = $79.53 billion
Antibacterial market = $44.5bn 2024
Right there thats a maximum of $243bn in just 4 markets. This doesnt include Dental implant market, Wound Care market, Oncology market via Cancer treatment applications and so many other markets Sintx could participate in. Hell im surprised Musks Neuralink hasnt tapped Sintx as the material would help with implantation both in reducing infection as well as reducing toxic corrosion.
People may look at this and think its ridiculous because Sintx is worth like 4.2m but its material is destined to replace current biomaterials in the ortho market. Its antiviral, antibacterial, antifungal so great product for catheter and PPE markets. Assuming it can be imbued in soap solutions obviously it would be great for the antibacterial markets as well. Its shows effectiveness against all ss-RNA viruses including Bird Flu & Covid. As well as they found its effective against herpes which is a double stranded DNA virus meaning it could be effective for the 10b condom market to help slow the spread of STIs.
Instantaneous Inactivation of Herpes Simplex Virus by Silicon Nitride Bioceramics
https://www.mdpi.com/1422-0067/24/16/12657
Funds watching Sintx:
https://fintel.io/so/us/sint
My post on markets Sintx can participate in with valuations and evidence:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174624826
Proof of short and distort campaign being waged against Sintx/SINT below.
Methods of Disinformation commonly being used in posts that are overly negative on Sintx. If those posting overly negative posts against Sintx were right, they wouldnt need to use disinformation tactics. They could just stick to the facts. They lack substance outside of things they can manipulate via the markets.
https://web.archive.org/web/20231004223836/https://www.ethosdebate.com/lies-rhetoric-4-18-rules-disinformation/
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
joev2
2 weeks ago
TA I don't know if this individual is a compensated shill or not, but if he isn't, he's most definitely the most stubborn, arrogant individual I've ever had a back and forth with on these boards. I've yet to hear him admit true wrong by himself or the company. Constant deflection along with the aim to steer the narrative in only one direction is his forte'. I'm sure the PERSONAL content of a post such as this, will be what he ONLY addresses, along with the other 17... Oh, and of course Bal's success and Sint's true worth....apparently missed by just...everybody else... LOL.
Hey Boston, would you care to divulge how much you have invested here, lost, or are willing to invest further? Seems kind of strange with all the accusations and innuendos from your side towards those opposing your views, that I have yet to see any numbers of anything invested coming from your end. Gives credence to the shill pov, imo.
joev2
2 weeks ago
Like I've said, you deflect, deflect, deflect. You have no interest in discussion, only in people agreeing with your views. I don't and won't because Sint remains a loser based on tons and tons of evidence that you willfully ignore. I have zero interest in delving deeper and deeper into doo-doo, okay? It makes no difference to me whatsoever (as I've stated many times) what Sint is or isn't intrinsically worth. So feel free to tell people I believe Sint is worth 50 billion. I don't care! Maybe it's true as well, okay?
Whether or not Bal got in bed with the wrong people on purpose or by ignorance and naivety (You'd be surprised how many startup ceos are ignorant of the vultures that surround them), the truth is he did and the results are the same for virtually every company which has done the same: a never ending death spiral. THAT is a FACT you continually and willfully ignore. And so you keep trying to rope people like myself into agreeing what a great company Sint is or will be or should be. No one listens or agrees. Doesn't matter what you say they SHOULD be worth.
They blew their chances long ago when they (for whatever reason) got into the death spiral routine thanks to the likes of Maxim and similar. And here they are, and here you are....longer than my eight years, but still spouting the same stuff that has gotten you nowhere, the company nowhere and the investment community nowhere. However, I'm sure some are travelling much lighter these days, thanks to their following your advice and/ or believing in Bal's leadership abilities.
Now feel free to once again post how I'm using disinfo tactics, personal attacks or posting negative stuff. Truth is, there's hardly a thing that isn't negative about Sint, including the alleged positives that are anything but, to the investor. Ask Bal. His supposed 1 million entry early on, leads me to believe he was duped by the Ascendiant and Maxim types (like many CEOs are) but to his credit, he has since learned. However, his disdain for fellow investors hasn't exactly endeared him, nor has his rewarding himself with bonuses for performance which is nothing short of horrendous (except to you). Enjoy ranting on my friend. I'll still probably respond in some fashion because I don't enjoy people losing their money (unless they refuse not to).
boston745
2 weeks ago
You've been posting here for about 8 years and have claimed to have invested in several stocks through the years. I think you can do better than I dont know. I dont know is the same as saying no comment without actually saying no comment which is a more evasive answer. A more honest answer would have been to say that you could see scenarios where its worth over 1 billion with the right commercialization partners. We both know Sintx depends on strategic partnerships for commercialization purposes.
Lets look at 4 markets Sintx can participate in to give an idea of potential worth. Mind you Sintx can play in more markets than this:
Global Ortho device market = $64bn by 2025
Global Catheter market = $55bn in 2023
Antibacterial market = $44.5bn 2024
Personal Protective Equipment market = $79.53 billion
Right there thats a maximum of $243bn in just 4 markets that Sintx can play in with antibacterial market being more murky as to if Si3N4 would be used in soaps and such. Thus Sintx need only achieve 1% market penetration to get to $2.4bn and .5% penetration to get to $1.2bn. As Sintx Silicon Nitride is destined to replace titanium and other biomaterials, i'd say its penetration of the ortho market alone would be way more than 1%. Given how effective Si3N4 is against different pathogens it should penetrate into the the catheter market far greater than 1% as well. So yes Sintx IP could easily justify being worth more than $1 billion specifically in the ortho device, catheter, & PPE markets. All the while Sintx current market valuation is ~$4.3m right now (best estimate based on 750k OS).
Orthopedics market set to reach $64bn by 2025 as acquisitions surge, says GlobalData
https://orthospinenews.com/2021/01/22/orthopedics-market-set-to-reach-64bn-by-2025-as-acquisitions-surge-says-globaldata/
The global catheter market size was estimated at USD 54.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.57% from 2024 to 2030.
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
Global antibacterial products market size is expected to reach $56.62 Bn by 2028 at a rate of 6.2%
https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report
The global personal protective equipment market size was over USD 79.53 billion in 2023 and is anticipated to grow at a CAGR of 7.2%
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Hot Features
Premium
